GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SillaJen Inc (XKRX:215600) » Definitions » Debt-to-Revenue

SillaJen (XKRX:215600) Debt-to-Revenue : 1.75 (As of Dec. 2024)


View and export this data going back to 2016. Start your Free Trial

What is SillaJen Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

SillaJen's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ₩10,123 Mil. SillaJen's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ₩566 Mil. SillaJen's annualized Revenue for the quarter that ended in Dec. 2024 was ₩6,107 Mil. SillaJen's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 was 1.75.


SillaJen Debt-to-Revenue Historical Data

The historical data trend for SillaJen's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SillaJen Debt-to-Revenue Chart

SillaJen Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.60 65.94 3.04 2.46 2.72

SillaJen Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A 8.21 3.15 2.02 1.75

Competitive Comparison of SillaJen's Debt-to-Revenue

For the Biotechnology subindustry, SillaJen's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SillaJen's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SillaJen's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where SillaJen's Debt-to-Revenue falls into.


;
;

SillaJen Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

SillaJen's Debt-to-Revenue for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(10123.384 + 565.906) / 3926.654
=2.72

SillaJen's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(10123.384 + 565.906) / 6106.528
=1.75

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2024) Revenue data.


SillaJen Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of SillaJen's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


SillaJen Business Description

Traded in Other Exchanges
N/A
Address
6F, 252, Geumjeong-ro, Geumjeong-gu, Busan, KOR, 46274
SillaJen Inc is a Korean based biotechnology company focused on engineering and developing cancer treatment cells. The company along with its subsidiary SillaJen Biotherapeutics, Inc offers Pexa-Vec, an oncolytic virus with antibodies, and improved survival in a randomized trial to cure cancer; and JX929, an engineered vaccinia virus strain that acts on cancer cells by viral attack and subsequent cancer cell oncolysis. SillaJen operates its business activities in Korea and United States.

SillaJen Headlines

No Headlines